Sotac Pharmaceuticals Limited engages in the production, manufacturing, processing, and sale of various pharmaceutical products in India. Its therapeutic product portfolio includes anti-diabetic, anti-psychotic, vitamins, minerals, iron supplements, anti-cold, anti-allergic, dermatological solutions, antacid, anti-ulcerants, PPI, anti-emetics, cardiac, anti-hypertensives, analgesic, anti-pyretic, anti-inflammatory, anti-bacterial, anti-viral, general antibiotics, IP-lactams and non-IP-lactams, anti-fungal, and cephalosporin products. The company also offers non-beta lactam general tablets, beta lactam coated tablets, beta lactam uncoated tablets, non-beta lactam general capsules, beta‐lactam capsules, oral liquid, dry syrup and external preparations such as nasal spray, relief spray and creams. In addition, it is involved in the research of pharmaceutical molecules used in developing new pharmaceutical formulations; and manufacture of nutraceuticals and food products. The company also
| Current Price | ₹90.05 |
|---|---|
| Market Cap | ₹100 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 17.3 |
| 52-Week Range | ₹86.00 – ₹139.65 |
| Beta (1Y) | -0.02 |
| Dividend Yield | 0.22% |
1. Pharmaceuticals-100%
Sotac Pharmaceuticals Limited is trading at ₹90.05, with a market capitalisation of ₹100 Cr.
Sotac Pharmaceuticals Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Sotac Pharmaceuticals Limited has a P/E of 17.3.